

# the POSNOC study

Site Newsletter - December 2017



**POS**itive **S**entinel **N**ode: adjuvant therapy alone versus adjuvant therapy plus **C**learance or axillary radiotherapy

**POSNOC is the largest UK led International breast cancer surgical trial**

## The Year in review

POSNOC has now recruited (n=913) more than twice as many patients with macrometastases recruited in Z11 (n=430)!

I recently met the first two women who had said YES to the study as part of their 3 year follow up visit. It is hard to believe 3 years have passed!

Women may experience arm swelling, shoulder problems, nerve pain, and numbness if all the lymph glands in the armpit are removed or treated with radiotherapy. However, if the treatment is not resulting in any benefit, should we be offering those treatments to women?

POSNOC will find out if armpit treatment is 'OVERTREATMENT' and reduce the side-effects for future women whose lives are changed by the word CANCER.

Together, we can [#makelymphoedemahistory](#)



Amit Goyal

Wishing you all a Merry Christmas and Happy New Year!

## Trial By Numbers

115

Sites participating in the trial  
(96 UK, 19 Australia and New Zealand)

913

Participants currently recruited into the trial




Thank you all for your contributions in the POSNOC study. With all your hard work we have managed to randomise **913** women into the trial to answer such an important question. Your enthusiasm and dedication to help women everywhere create a better standard of care is making this study happen.

*Thank you!*



## Investigator Meetings 2017

2017 saw five successful Regional Investigator meetings held in the first half of the year. We hope the presentation and discussion sessions were useful in supporting you with any challenges which were identified at your sites. We hope that you found our hints and tips useful and you've been able to implement some of these into your recruitment approaches and processes.



*Interdisciplinary Breast Cancer Symposium (IBCS)  
We will be attending the first UK IBCS meeting in January 2018.  
Please do come over and say hello - it will be great to put some names to faces. We hope to see you all there in the new year.*

## Substantial Amendment 03 & 04

We know that the main reason for women choosing not to participate in the trial is that they have a preference for their treatment and from talking to you, we also know that informing women about the POSNOC study as early as possible is important. With this in mind, we have revamped our patient information material – we now have several layers of information, depending upon the time point at which a woman is being approached. Once this documentation has been approved we will provide you with copies. The protocol has also been amended – again, once we have received approval, you will be sent this.

## Safety & Holiday Cover 2017



Nottingham CTU closure: Friday 22nd December until Wednesday 3rd January 2018  
SAEs: Report as usual - Fax to **0115 7484091**

E-mail to [NCTU-SAE@nottingham.ac.uk](mailto:NCTU-SAE@nottingham.ac.uk).

SAEs will continue to be monitored and processed daily during this time.

IT request: email [NCTU-IT@nottingham.ac.uk](mailto:NCTU-IT@nottingham.ac.uk) and mark your email as urgent.

Note: this inbox will be checked once a day during the Christmas period. You should only report problems that are urgent for that day - i.e. unable to randomise.

For any general trial queries please get in touch with your study coordinating team:

### UK

#### Nottingham Clinical Trials Unit

Trial Manager: Beki Haydock

Tel: 0115 82 31575

Email: [POSNOC@nottingham.ac.uk](mailto:POSNOC@nottingham.ac.uk)

### SHORE-C

Kathryn Monson

Tel: 01273 873034

Email: [K.Monson@sussex.ac.uk](mailto:K.Monson@sussex.ac.uk)

### ANZ

Breast Cancer Trials

[breastcancertrials.org.au](http://breastcancertrials.org.au)

### Chief Investigator

Amit Goyal

[amit.goyal@nhs.net](mailto:amit.goyal@nhs.net)



follow us on Twitter @POSNOC

Wishing you all a very **Merry Christmas** and a **Prosperous New Year!**